Trial Profile
A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Moderately to Severely Active Ulcerative Colitis.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Dec 2021
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Acronyms ULTRA-2
- Sponsors Abbott Laboratories
- 27 Oct 2021 Results of a comparative analysis of TRUE NORTH study versus ULTRA 1, ULTRA 2 and GEMINI 1 studies data presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2021
- 27 Jan 2018 Results assessing the safety of Adalimumab Dosed Every Week and Every Other Week in patients from this and 12 other studies, published in the American Journal of Clinical Dermatology
- 07 Nov 2016 Results of post hoc analysis of this and other five studies (CLASSIC-I, GAIN, CHARM, EXTEND, ULTRA 1 AND ULTRA 2) published in the Alimentary Pharmacology and Therapeutics